

Pembrolizumab KEYNOTE-002

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments




Long term plateau in the PFS curve



Pembrolizumab KEYNOTE-002

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma  
Experimental Arm: Pembrolizumab  
Control Arm: Investigator-choice chemotherapy (Randomised phase II study)

